Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is adv...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

BanditQ Jul. 17 at 5:47 PM

$CUE

1 · Reply

Dr_Stoxx Jul. 16 at 4:54 PM

Our 3 Momentum SHORTS this week. How are we doing? Momentum Letter: our most profitable service since 2015. $DWSN $CUE $PENG

1 · Reply

BanditQ Jul. 16 at 1:57 PM

$CUE wouldn't give a fuck if it went to 0

1 · Reply

SirDuncan11 Jul. 15 at 4:17 PM

$CUE still plenty of room to go down

0 · Reply

SirDuncan11 Jul. 14 at 4:11 PM

$CUE down 20% since my post

0 · Reply

BanditQ Jul. 14 at 12:38 PM

$CUE relax and take some sip of cola 👍

0 · Reply

Relee187200 Jul. 13 at 6:29 PM

$CUE Damn!!

2 · Reply

BanditQ Jul. 13 at 6:03 PM

$CUE doubled my position, give me that clean chinese data. I'll use my gains for evil as always. $EQ $TENX

1 · Reply

BanditQ Jul. 13 at 2:52 PM

$CUE and this matters because? What does the stockprice fluctuation have to do with the data read out?

1 · Reply

SirDuncan11 Jul. 13 at 2:16 PM

$CUE down 13% so far still some room to fall further

0 · Reply

Cue Biopharma appoints Dominic Borie as chief medical officer

KYTX

Jul 13, 2026, 8:30 AM EDT - 7 days ago

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

2026-07-10T09:15:14.000Z - 10 days ago

Cue Biopharma to sell 1.418M shares at $33.21 in private placement

Jul 9, 2026, 9:40 PM EDT - 10 days ago

Cue Biopharma Announces $50.0 Million Private Placement

2026-06-18T20:11:28.000Z - 4 weeks ago

Cue Biopharma files to sell 551,724 shares of common stock for holders

Jun 18, 2026, 8:00 AM EDT - 4 weeks ago

Cue Biopharma Registration statement: Registration filing

2026-06-03T20:21:57.000Z - 6 weeks ago

Cue Biopharma registers to sell 4.09M shares of common stock for holders

Jun 3, 2026, 3:10 PM EDT - 6 weeks ago

Cue Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:10 PM EDT - 6 weeks ago

Cue Biopharma Slides: FY 2026

Jun 3, 2026, 8:00 AM EDT - 6 weeks ago

Cue Biopharma Registration statement: Registration filing

2026-06-02T20:41:36.000Z - 6 weeks ago

Cue Biopharma announces board transition, appoints two new directors

Jun 2, 2026, 4:05 PM EDT - 6 weeks ago

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

Jun 1, 2026, 9:00 AM EDT - 6 weeks ago

Cue Biopharma Transcript: EGM 2026

May 21, 2026, 4:05 PM EDT - 2 months ago

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference

May 21, 2026, 8:00 AM EDT - 2 months ago

Cue Biopharma Proxy statement: Proxy filing

May 14, 2026, 4:07 PM EDT - 2 months ago

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

May 14, 2026, 7:00 AM EDT - 2 months ago

Cue Biopharma Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Cue Biopharma Earnings release: Q1 2026

May 11, 2026, 8:00 AM EDT - 2 months ago

Cue Biopharma Proxy statement: Proxy filing

May 7, 2026, 7:07 PM EDT - 2 months ago

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-04T17:37:20.000Z - 2 months ago

Cue Biopharma trading resumes

2026-05-04T17:31:09.000Z - 2 months ago

Cue Biopharma trading halted, volatility trading pause

2026-05-01T12:53:12.000Z - 2 months ago

Why Is Cue Biopharma Stock Up Today?

2026-04-30T21:13:55.000Z - 2 months ago

Cue Biopharma appoints Shao-Lee Lin as CEO

2026-04-30T21:04:54.000Z - 2 months ago

Cue Biopharma announces $30M private placement

Apr 30, 2026, 4:25 PM EDT - 2 months ago

Cue Biopharma Announces $30 Million Private Placement

Apr 30, 2026, 4:15 PM EDT - 2 months ago

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

2026-04-28T13:54:10.000Z - 2 months ago

Cue Biopharma trading halted, volatility trading pause

2026-04-28T13:48:36.000Z - 2 months ago

Cue Biopharma trading resumes

2026-04-27T14:37:18.000Z - 2 months ago

Cue Biopharma trading resumes

2026-04-27T13:47:34.000Z - 2 months ago

Cue Biopharma trading halted, volatility trading pause

2026-04-24T13:48:28.000Z - 3 months ago

Cue Biopharma trading resumes

2026-04-24T13:37:14.000Z - 3 months ago

Cue Biopharma trading halted, volatility trading pause

2026-04-23T23:50:37.000Z - 3 months ago

Cue Biopharma trading halted, news pending

2026-04-22T14:15:23.000Z - 3 months ago

Cue Biopharma announces 1-for-30 reverse stock split

Apr 22, 2026, 8:37 AM EDT - 3 months ago

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Apr 13, 2026, 9:00 AM EDT - 3 months ago

Cue Biopharma Transcript: AGM 2026

2026-04-08T12:15:20.000Z - 3 months ago

Cue Biopharma to receive $7.5M milestone payment from Boehringer Ingelheim pact

Apr 8, 2026, 8:00 AM EDT - 3 months ago

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Apr 7, 2026, 10:00 AM EDT - 3 months ago

Cue Biopharma Transcript: R&D Day 2026

Apr 7, 2026, 10:00 AM EDT - 3 months ago

Cue Biopharma Slides: FY 2026

Mar 27, 2026, 4:05 PM EDT - 4 months ago

Cue Biopharma Announces CEO Transition

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Cue Biopharma Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 4 months ago

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Mar 16, 2026, 4:05 PM EDT - 4 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 16, 2026, 8:00 AM EDT - 4 months ago

Cue Biopharma Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 4 months ago

Cue Biopharma Registration statement: Registration Filing

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Cue Biopharma Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Cue Biopharma Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Cue Biopharma Annual report: Q4 2025

Mar 9, 2026, 8:00 AM EDT - 4 months ago

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

Mar 6, 2026, 7:00 AM EST - 4 months ago

Cue Biopharma Proxy statement: Proxy Filing

Feb 17, 2026, 8:00 AM EST - 5 months ago

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

Feb 12, 2026, 8:00 AM EST - 5 months ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

Dec 19, 2025, 8:00 AM EST - 7 months ago

Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 4:02 PM EST - 7 months ago

Cue Biopharma Announces Proposed Public Offering

Nov 12, 2025, 4:05 PM EST - 8 months ago

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:00 AM EST - 8 months ago

Cue Biopharma Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Cue Biopharma Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Sep 29, 2025, 9:00 AM EDT - 10 months ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Sep 5, 2025, 8:00 AM EDT - 11 months ago

Cue Biopharma Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Cue Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Cue Biopharma Earnings release: Q2 2025

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 1 year ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 1 year ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 27, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma Proxy statement: Proxy Filing

May 15, 2025, 11:00 AM EDT - 1 year ago

Cue Biopharma Transcript: Status Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 12, 2025, 4:00 PM EDT - 1 year ago

Cue Biopharma Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Cue Biopharma Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 1 year ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma Proxy statement: Proxy Filing

Apr 15, 2025, 4:30 PM EDT - 1 year ago

Cue Biopharma Transcript: Status Update

Apr 15, 2025, 2:00 AM EDT - 1 year ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:02 PM EDT - 1 year ago

Cue Biopharma to Host Business Update Call and Webcast

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma Proxy statement: Proxy Filing

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 31, 2025, 12:00 AM EDT - 1 year ago

Cue Biopharma Earnings release: Q4 2024

Mar 31, 2025, 12:00 AM EDT - 1 year ago

Cue Biopharma Annual report: Q4 2024

Dec 4, 2024, 9:00 AM EST - 1 year ago

Cue Biopharma Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 1:15 PM EST - 1 year ago

Cue Biopharma Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 14, 2024, 12:00 AM EST - 1 year ago

Cue Biopharma Earnings release: Q3 2024

Nov 14, 2024, 12:00 AM EST - 1 year ago

Cue Biopharma Quarterly report: Q3 2024

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 10, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma Proxy statement: Proxy Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 28, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma Proxy statement: Proxy Filing

Aug 19, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Earnings Call Transcript: Q2 2024

Aug 19, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Quarterly report: Q2 2024

Aug 19, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Earnings release: Q2 2024

Aug 19, 2024, 4:05 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 6, 2024, 2:00 PM EDT - 2 years ago

Cue Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

May 24, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma Proxy statement: Proxy Filing

May 14, 2024, 12:00 PM EDT - 2 years ago

Cue Biopharma Transcript: The Citizens JMP Life Sciences Conference

May 9, 2024, 4:00 PM EDT - 2 years ago

Cue Biopharma Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Cue Biopharma Earnings release: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma Proxy statement: Proxy Filing

Apr 24, 2024, 10:01 AM EDT - 2 years ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Earnings Call Transcript: Q4 2023

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Earnings release: Q4 2023

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Annual report: Q4 2023

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Apr 8, 2024, 10:00 AM EDT - 2 years ago

Cue Biopharma Slides: Investor Presentation

Feb 29, 2024, 10:00 AM EST - 2 years ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Feb 13, 2024, 9:20 AM EST - 2 years ago

Cue Biopharma Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Nov 29, 2023, 4:00 PM EST - 2 years ago

Cue Biopharma Transcript: The Piper Sandler 35th Annual Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BanditQ Jul. 17 at 5:47 PM

$CUE

1 · Reply

Dr_Stoxx Jul. 16 at 4:54 PM

Our 3 Momentum SHORTS this week. How are we doing? Momentum Letter: our most profitable service since 2015. $DWSN $CUE $PENG

1 · Reply

BanditQ Jul. 16 at 1:57 PM

$CUE wouldn't give a fuck if it went to 0

1 · Reply

SirDuncan11 Jul. 15 at 4:17 PM

$CUE still plenty of room to go down

0 · Reply

SirDuncan11 Jul. 14 at 4:11 PM

$CUE down 20% since my post

0 · Reply

BanditQ Jul. 14 at 12:38 PM

$CUE relax and take some sip of cola 👍

0 · Reply

Relee187200 Jul. 13 at 6:29 PM

$CUE Damn!!

2 · Reply

BanditQ Jul. 13 at 6:03 PM

$CUE doubled my position, give me that clean chinese data. I'll use my gains for evil as always. $EQ $TENX

1 · Reply

BanditQ Jul. 13 at 2:52 PM

$CUE and this matters because? What does the stockprice fluctuation have to do with the data read out?

1 · Reply

SirDuncan11 Jul. 13 at 2:16 PM

$CUE down 13% so far still some room to fall further

0 · Reply

SirDuncan11 Jul. 13 at 2:32 AM

$CUE due for a plummet post dilution

3 · Reply

AXLFI_HQ Jul. 11 at 12:30 AM

$CUE Small-cap and micro-cap companies are executing dilutive equity financing through warrant exercises, private placements, and equity lines of credit at steep discounts to market prices, reflecting capital market access constraints and investor preference for downside protection. Learn more: https://axlfi.com/themes/421

0 · Reply

BanditQ Jul. 10 at 10:42 PM

$CUE sorry for -6% guys

0 · Reply

BanditQ Jul. 10 at 5:47 PM

$CUE started small position here 1000 shares. We'll see what happens IDGAFF

0 · Reply

SirDuncan11 Jul. 10 at 4:43 PM

$CUE dilution, the Cue Biopharma way

1 · Reply

LabPsycho Jul. 10 at 1:49 PM

$CUE Why do a raise before the data - esp when they had sufficient cash through the read? Think people.....

2 · Reply

ill_Freaky_na_na Jul. 10 at 1:47 PM

$CUE Squeeze?

0 · Reply

Stock_Catcher Jul. 10 at 1:45 PM

$CUE Hourly Heat

0 · Reply

daprinta Jul. 10 at 1:37 PM

$CUE I’ve been a buyer for quite some time… I reiterate a strong BUY… with the forthcoming data;CUE…IMO will be $60 sooner than later… Strap yourself in!!!

1 · Reply

Relee187200 Jul. 10 at 1:23 PM

$CUE Up in pre market? Strange.

0 · Reply

JFais Jul. 10 at 1:11 PM

$CUE raised $50M at close with no warrants, led by Cormorant 🧐 Results from China phase 2 in CSU expected this quarter for CUE-221 (dual MOA anti-IgE, essentially higher potency Xolair with higher binding affinity & slower off-rate)

1 · Reply

smolcapcat Jul. 10 at 10:44 AM

$CUE a well known and trusted biotech investment firm just gave these guys a big cheque... did they do that because they're idiots, or because the upcoming data is going to be baller and send the stock much, much higher than here? time will tell, but the dilution doesn't really matter here if the latter

0 · Reply

Market Cap	130.88M
Revenue (ttm)	27.47M
Net Income (ttm)	-26.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.83%
Debt to Equity Ratio	0.00

Volume	122,600
Avg Vol	139,884
Day's Range	N/A - N/A
Shares Out	4.20M
Stochastic %K	28%
Beta	2.45
Analysts	Strong Sell
Price Target	$98.39